{"entity":{"type":"insider","cik":"0001354395","url":"/insider/0001354395","json_url":"/insider/0001354395.json","name":"Deerfield Special Situations Fund, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":1117,"n_filings":195,"first":"2006-02-24","last":"2021-07-13","span_basis":"filed_date"},"name_variants":[{"name":"Deerfield Special Situations Fund, L.P.","source":"filing","n_filings":195,"first_seen":"2006-02-24","last_seen":"2021-07-13"}],"transactions":[{"id":5512428,"accession":"0001193805-21-001014","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-21-001014","line_url":"/filing/0001193805-21-001014#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Private Design Fund IV, L.P.","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":99325.0,"shares_display":"99,325","price_per_share":15.81,"price_display":"15.81","price_state":"stated","total_value":1570328.25,"total_display":"1,570,328.25","total_whole":"1,570,328","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-09","filed_date":"2021-07-13","scope":"insider"},{"id":5471352,"accession":"0001193805-21-000999","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-21-000999","line_url":"/filing/0001193805-21-000999#line-3","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6837.0,"shares_display":"6,837","price_per_share":15.869,"price_display":"15.87","price_state":"stated","total_value":108496.353,"total_display":"108,496.35","total_whole":"108,496","shares_owned_after":99325.0,"shares_owned_after_display":"99,325","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-07","filed_date":"2021-07-07","scope":"insider"},{"id":5471349,"accession":"0001193805-21-000999","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-21-000999","line_url":"/filing/0001193805-21-000999#line-2","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":49239.0,"shares_display":"49,239","price_per_share":16.195,"price_display":"16.20","price_state":"stated","total_value":797425.605,"total_display":"797,425.60","total_whole":"797,426","shares_owned_after":106162.0,"shares_owned_after_display":"106,162","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-06","filed_date":"2021-07-07","scope":"insider"},{"id":5471346,"accession":"0001193805-21-000999","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-21-000999","line_url":"/filing/0001193805-21-000999#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt HIF, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Private Design Fund IV, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10599.0,"shares_display":"10,599","price_per_share":17.011,"price_display":"17.01","price_state":"stated","total_value":180299.589,"total_display":"180,299.59","total_whole":"180,300","shares_owned_after":155401.0,"shares_owned_after_display":"155,401","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-02","filed_date":"2021-07-07","scope":"insider"},{"id":8673369,"accession":"0001193805-19-001376","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-19-001376","line_url":"/filing/0001193805-19-001376#line-3","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Cabaletta Bio, Inc.","issuer_ticker":"CABA","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt IV, L.P.; Deerfield Mgmt L.P.; Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Special Situations Fund, L.P.; Deerfield Private Design Fund IV, L.P.; DEERFIELD PARTNERS, L.P.","owner_display_name":"Deerfield Mgmt IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":700000.0,"shares_display":"700,000","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":7700000.0,"total_display":"7,700,000.00","total_whole":"7,700,000","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-10-29","filed_date":"2019-10-30","scope":"insider"},{"id":8723523,"accession":"0001193805-19-000911","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-19-000911","line_url":"/filing/0001193805-19-000911#line-3","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Frequency Therapeutics, Inc.","issuer_ticker":"FREQ","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund IV, L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Mgmt L.P.; Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt IV, L.P.; DEERFIELD PARTNERS, L.P.","owner_display_name":"Deerfield Private Design Fund IV, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":285714.0,"shares_display":"285,714","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":3999996.0,"total_display":"3,999,996.00","total_whole":"3,999,996","shares_owned_after":285714.0,"shares_owned_after_display":"285,714","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-10-07","filed_date":"2019-10-07","scope":"insider"},{"id":8062504,"accession":"0001193805-19-000660","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-19-000660","line_url":"/filing/0001193805-19-000660","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Mirum Pharmaceuticals, Inc.","issuer_ticker":"MIRM","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Healthcare Innovations Fund, L.P.; Deerfield Mgmt L.P.; Deerfield Mgmt IV, L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Mgmt HIF, L.P.; Deerfield Private Design Fund IV, L.P.","owner_display_name":"Deerfield Healthcare Innovations Fund, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":332000.0,"shares_display":"332,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":4980000.0,"total_display":"4,980,000.00","total_whole":"4,980,000","shares_owned_after":1724456.0,"shares_owned_after_display":"1,724,456","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-07-22","filed_date":"2019-07-24","scope":"insider","n_lines":2},{"id":7919915,"accession":"0001193805-19-000616","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-19-000616","line_url":"/filing/0001193805-19-000616","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD PARTNERS, L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; Flynn James E","owner_display_name":"DEERFIELD PARTNERS, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":699475.0,"shares_display":"699,475","price_per_share":2.6907,"price_display":"2.69","price_state":"stated","total_value":1882077.3825,"total_display":"1,882,077.38","total_whole":"1,882,077","shares_owned_after":3159165.0,"shares_owned_after_display":"3,159,165","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-27","filed_date":"2019-07-01","scope":"insider","n_lines":2},{"id":8135185,"accession":"0001193805-19-000603","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-19-000603","line_url":"/filing/0001193805-19-000603","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Flynn James E; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.","owner_display_name":"Flynn James E","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1704.0,"shares_display":"1,704","price_per_share":4.5015,"price_display":"4.50","price_state":"stated","total_value":7670.556,"total_display":"7,670.56","total_whole":"7,671","shares_owned_after":3749966.0,"shares_owned_after_display":"3,749,966","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-26","filed_date":"2019-06-26","scope":"insider","n_lines":2},{"id":7835333,"accession":"0001193805-19-000599","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193805-19-000599","line_url":"/filing/0001193805-19-000599","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD PARTNERS, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51484.0,"shares_display":"51,484","price_per_share":4.5089,"price_display":"4.51","price_state":"stated","total_value":232136.2076,"total_display":"232,136.21","total_whole":"232,136","shares_owned_after":3751318.0,"shares_owned_after_display":"3,751,318","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-25","filed_date":"2019-06-25","scope":"insider","n_lines":2},{"id":7835328,"accession":"0001193805-19-000599","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-19-000599","line_url":"/filing/0001193805-19-000599","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD PARTNERS, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63240.0,"shares_display":"63,240","price_per_share":4.5225,"price_display":"4.52","price_state":"stated","total_value":286002.9,"total_display":"286,002.90","total_whole":"286,003","shares_owned_after":3792168.0,"shares_owned_after_display":"3,792,168","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-24","filed_date":"2019-06-25","scope":"insider","n_lines":2},{"id":7835323,"accession":"0001193805-19-000599","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-19-000599","line_url":"/filing/0001193805-19-000599","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD PARTNERS, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":339537.0,"shares_display":"339,537","price_per_share":4.6154,"price_display":"4.62","price_state":"stated","total_value":1567099.0698,"total_display":"1,567,099.07","total_whole":"1,567,099","shares_owned_after":3842345.0,"shares_owned_after_display":"3,842,345","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-21","filed_date":"2019-06-25","scope":"insider","n_lines":2},{"id":8062489,"accession":"0001193805-19-000485","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-19-000485","line_url":"/filing/0001193805-19-000485","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Special Situations Fund, L.P.; Flynn James E; Deerfield Mgmt L.P.","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":180565.0,"shares_display":"180,565","price_per_share":6.0492,"price_display":"6.05","price_state":"stated","total_value":1092273.798,"total_display":"1,092,273.80","total_whole":"1,092,274","shares_owned_after":4111747.0,"shares_owned_after_display":"4,111,747","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-10","filed_date":"2019-05-13","scope":"insider","n_lines":2},{"id":8062482,"accession":"0001193805-19-000485","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-19-000485","line_url":"/filing/0001193805-19-000485","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Special Situations Fund, L.P.; Flynn James E; Deerfield Mgmt L.P.","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":434145.0,"shares_display":"434,145","price_per_share":6.1575,"price_display":"6.16","price_state":"stated","total_value":2673247.8375,"total_display":"2,673,247.84","total_whole":"2,673,248","shares_owned_after":4220443.0,"shares_owned_after_display":"4,220,443","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-09","filed_date":"2019-05-13","scope":"insider","n_lines":2},{"id":8310803,"accession":"0001193805-19-000271","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001193805-19-000271","line_url":"/filing/0001193805-19-000271","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"ShockWave Medical, Inc.","issuer_ticker":"SWAV","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":510000.0,"total_display":"510,000.00","total_whole":"510,000","shares_owned_after":166073.0,"shares_owned_after_display":"166,073","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-11","filed_date":"2019-03-11","scope":"insider","n_lines":3},{"id":7787081,"accession":"0001193805-19-000209","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-19-000209","line_url":"/filing/0001193805-19-000209#line-2","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Flynn James E; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Special Situations Fund, L.P.","owner_display_name":"Deerfield Private Design Fund III, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1351.0,"shares_display":"1,351","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":20265.0,"total_display":"20,265.00","total_whole":"20,265","shares_owned_after":856470.0,"shares_owned_after_display":"856,470","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-11","filed_date":"2019-02-12","scope":"insider"},{"id":7787079,"accession":"0001193805-19-000209","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-19-000209","line_url":"/filing/0001193805-19-000209#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Flynn James E; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Special Situations Fund, L.P.","owner_display_name":"Deerfield Private Design Fund III, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5890.0,"shares_display":"5,890","price_per_share":15.1079,"price_display":"15.11","price_state":"stated","total_value":88985.531,"total_display":"88,985.53","total_whole":"88,986","shares_owned_after":857821.0,"shares_owned_after_display":"857,821","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-08","filed_date":"2019-02-12","scope":"insider"},{"id":8554695,"accession":"0001193805-19-000117","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-19-000117","line_url":"/filing/0001193805-19-000117#line-3","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9409.0,"shares_display":"9,409","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":141135.0,"total_display":"141,135.00","total_whole":"141,135","shares_owned_after":863711.0,"shares_owned_after_display":"863,711","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-07","filed_date":"2019-02-07","scope":"insider"},{"id":8554693,"accession":"0001193805-19-000117","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-19-000117","line_url":"/filing/0001193805-19-000117#line-2","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":6000.0,"total_display":"6,000.00","total_whole":"6,000","shares_owned_after":873120.0,"shares_owned_after_display":"873,120","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-06","filed_date":"2019-02-07","scope":"insider"},{"id":8554689,"accession":"0001193805-19-000117","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-19-000117","line_url":"/filing/0001193805-19-000117#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4998.0,"shares_display":"4,998","price_per_share":15.0676,"price_display":"15.07","price_state":"stated","total_value":75307.8648,"total_display":"75,307.86","total_whole":"75,308","shares_owned_after":873520.0,"shares_owned_after_display":"873,520","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-05","filed_date":"2019-02-07","scope":"insider"},{"id":8230296,"accession":"0001193805-19-000102","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-19-000102","line_url":"/filing/0001193805-19-000102#line-2","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Private Design Fund III, L.P.; Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; Flynn James E; Deerfield Mgmt III, L.P.","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6210.0,"shares_display":"6,210","price_per_share":15.1414,"price_display":"15.14","price_state":"stated","total_value":94028.094,"total_display":"94,028.09","total_whole":"94,028","shares_owned_after":878518.0,"shares_owned_after_display":"878,518","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-29","filed_date":"2019-01-30","scope":"insider"},{"id":8230290,"accession":"0001193805-19-000102","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-19-000102","line_url":"/filing/0001193805-19-000102#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Private Design Fund III, L.P.; Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; Flynn James E; Deerfield Mgmt III, L.P.","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":828.0,"shares_display":"828","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":12420.0,"total_display":"12,420.00","total_whole":"12,420","shares_owned_after":884728.0,"shares_owned_after_display":"884,728","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-28","filed_date":"2019-01-30","scope":"insider"},{"id":8002923,"accession":"0001193805-19-000089","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193805-19-000089","line_url":"/filing/0001193805-19-000089#line-3","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Special Situations Fund, L.P.","owner_display_name":"Deerfield Private Design Fund III, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":76820.0,"shares_display":"76,820","price_per_share":15.0775,"price_display":"15.08","price_state":"stated","total_value":1158253.55,"total_display":"1,158,253.55","total_whole":"1,158,254","shares_owned_after":885556.0,"shares_owned_after_display":"885,556","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-25","filed_date":"2019-01-25","scope":"insider"},{"id":8002920,"accession":"0001193805-19-000089","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-19-000089","line_url":"/filing/0001193805-19-000089#line-2","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Special Situations Fund, L.P.","owner_display_name":"Deerfield Private Design Fund III, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5425.0,"shares_display":"5,425","price_per_share":15.0346,"price_display":"15.03","price_state":"stated","total_value":81562.705,"total_display":"81,562.70","total_whole":"81,563","shares_owned_after":962376.0,"shares_owned_after_display":"962,376","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-24","filed_date":"2019-01-25","scope":"insider"},{"id":8002916,"accession":"0001193805-19-000089","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-19-000089","line_url":"/filing/0001193805-19-000089#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Private Design Fund III, L.P.; Deerfield Mgmt III, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Special Situations Fund, L.P.","owner_display_name":"Deerfield Private Design Fund III, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32199.0,"shares_display":"32,199","price_per_share":16.3476,"price_display":"16.35","price_state":"stated","total_value":526376.3724,"total_display":"526,376.37","total_whole":"526,376","shares_owned_after":967801.0,"shares_owned_after_display":"967,801","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-01-23","filed_date":"2019-01-25","scope":"insider"},{"id":6894805,"accession":"0001193805-18-001183","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193805-18-001183","line_url":"/filing/0001193805-18-001183","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"ARVINAS INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Private Design Fund III, L.P.; Deerfield Mgmt IV, L.P.; Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; Deerfield Private Design Fund IV, L.P.; Flynn James E; Deerfield Mgmt III, L.P.","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":312500.0,"shares_display":"312,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":411245.0,"shares_owned_after_display":"411,245","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-01","scope":"insider","n_lines":3},{"id":6285732,"accession":"0001193805-18-001002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193805-18-001002","line_url":"/filing/0001193805-18-001002#line-2","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"CONSTELLATION PHARMACEUTICALS INC","issuer_ticker":"CNST","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Flynn James E; Deerfield Special Situations Fund, L.P.","owner_display_name":"Deerfield Mgmt L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":835843.0,"shares_owned_after_display":"835,843","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-07-23","filed_date":"2018-07-23","scope":"insider"},{"id":6464169,"accession":"0001193805-18-000920","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193805-18-000920","line_url":"/filing/0001193805-18-000920","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"XERIS PHARMACEUTICALS INC","issuer_ticker":"XERS","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Special Situations Fund, L.P.; Deerfield Mgmt L.P.; Deerfield Mgmt III, L.P.; Deerfield Private Design Fund III, L.P.; Flynn James E","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":750000.0,"shares_display":"750,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":11250000.0,"total_display":"11,250,000.00","total_whole":"11,250,000","shares_owned_after":1498666.0,"shares_owned_after_display":"1,498,666","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-27","scope":"insider","n_lines":2},{"id":6096261,"accession":"0001193805-18-000909","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193805-18-000909","line_url":"/filing/0001193805-18-000909#line-1","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"AVADEL PHARMACEUTICALS PLC","issuer_ticker":"AVDL","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"Deerfield Special Situations Fund, L.P.; Deerfield Mgmt L.P.; DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Private Design Fund II, L.P.; Flynn James E; Breaking Stick Holdings, LLC; Deerfield Private Design International II, L.P.","owner_display_name":"Deerfield Special Situations Fund, L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"American Depositary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114034.0,"shares_display":"114,034","price_per_share":5.9922,"price_display":"5.99","price_state":"stated","total_value":683314.5348,"total_display":"683,314.53","total_whole":"683,315","shares_owned_after":952265.0,"shares_owned_after_display":"952,265","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-25","scope":"insider"},{"id":6074783,"accession":"0001193805-18-000778","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193805-18-000778","line_url":"/filing/0001193805-18-000778","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"Kiniksa Pharmaceuticals, Ltd.","issuer_ticker":"KNSA","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); Deerfield Mgmt L.P.; DEERFIELD PARTNERS, L.P.; Deerfield Special Situations Fund, L.P.; Flynn James E","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":843352.0,"shares_display":"843,352","price_per_share":18.96815860222066,"price_display":"18.97","price_state":"stated","total_value":15996834.4935,"total_display":"15,996,834.49","total_whole":"15,996,834","shares_owned_after":333333.0,"shares_owned_after_display":"333,333","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-29","filed_date":"2018-05-31","scope":"insider","n_lines":4},{"id":9256097,"accession":"0001193805-18-000436","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001193805-18-000436","line_url":"/filing/0001193805-18-000436","is_derivative":false,"issuer_cik":"0001009258","issuer_name":"CATALYST BIOSCIENCES, INC.","issuer_ticker":"CBIO","issuer_name_source":null,"issuer_url":"/issuer/0001009258","owner_cik":null,"owner_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt L.P.; Deerfield Special Situations Fund, L.P.; Flynn James E","owner_display_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9317.0,"shares_display":"9,317","price_per_share":29.15430825372974,"price_display":"29.15","price_state":"stated","total_value":271630.69,"total_display":"271,630.69","total_whole":"271,631","shares_owned_after":305965.0,"shares_owned_after_display":"305,965","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-03-08","filed_date":"2018-03-21","scope":"insider","n_lines":4}],"collapsed":true,"next_cursor":"2018-03-08|9256094","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001759425","name":"Mirum Pharmaceuticals, Inc.","url":"/issuer/0001759425","role":"Ten percent owner, Other","n_filings":3,"first_seen":"2019-07-24","last_seen":"2021-07-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001759138","name":"Cabaletta Bio, Inc.","url":"/issuer/0001759138","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2019-10-30","last_seen":"2019-10-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001703647","name":"Frequency Therapeutics, Inc.","url":"/issuer/0001703647","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2019-10-07","last_seen":"2019-10-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001557746","name":"Aclaris Therapeutics, Inc.","url":"/issuer/0001557746","role":"Other","n_filings":4,"first_seen":"2019-05-13","last_seen":"2019-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001642545","name":"ShockWave Medical, Inc.","url":"/issuer/0001642545","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2019-03-11","last_seen":"2019-03-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001346302","name":"XERIS PHARMACEUTICALS INC","url":"/issuer/0001346302","role":"Ten percent owner, Other","n_filings":5,"first_seen":"2018-06-27","last_seen":"2019-02-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001655759","name":"ARVINAS INC.","url":"/issuer/0001655759","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2018-10-01","last_seen":"2018-10-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001434418","name":"CONSTELLATION PHARMACEUTICALS INC","url":"/issuer/0001434418","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2018-07-23","last_seen":"2018-07-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001012477","name":"AVADEL PHARMACEUTICALS PLC","url":"/issuer/0001012477","role":"Other","n_filings":1,"first_seen":"2018-06-25","last_seen":"2018-06-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001730430","name":"Kiniksa Pharmaceuticals, Ltd.","url":"/issuer/0001730430","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2018-05-31","last_seen":"2018-05-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001124105","name":"CATALYST BIOSCIENCES, INC.","url":"/issuer/0001124105","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2018-03-08","last_seen":"2018-03-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001649904","name":"RHYTHM PHARMACEUTICALS, INC.","url":"/issuer/0001649904","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2017-10-10","last_seen":"2017-10-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001588972","name":"Recro Pharma, Inc.","url":"/issuer/0001588972","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2017-06-09","last_seen":"2017-06-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001333493","name":"eHealth, Inc.","url":"/issuer/0001333493","role":"Ten percent owner, Other","n_filings":8,"first_seen":"2016-05-27","last_seen":"2017-04-27"},{"type":"issuer","type_label":"ISSUER","cik":"0000764579","name":"CAS MEDICAL SYSTEMS INC","url":"/issuer/0000764579","role":"Ten percent owner, Other","n_filings":3,"first_seen":"2015-01-05","last_seen":"2017-01-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001393020","name":"Invuity, Inc.","url":"/issuer/0001393020","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2016-12-14","last_seen":"2016-12-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001347178","name":"Vanda Pharmaceuticals Inc.","url":"/issuer/0001347178","role":"Ten percent owner, Other","n_filings":5,"first_seen":"2015-12-11","last_seen":"2016-09-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001374690","name":"ZAFGEN, INC.","url":"/issuer/0001374690","role":"Ten percent owner, Other","n_filings":3,"first_seen":"2016-02-11","last_seen":"2016-08-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001628738","name":"Audentes Therapeutics, Inc.","url":"/issuer/0001628738","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2016-07-25","last_seen":"2016-07-25"},{"type":"issuer","type_label":"ISSUER","cik":"0000805928","name":"AxoGen, Inc.","url":"/issuer/0000805928","role":"Ten percent owner, Other","n_filings":4,"first_seen":"2015-04-09","last_seen":"2016-07-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001556263","name":"Syros Pharmaceuticals, Inc.","url":"/issuer/0001556263","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2016-07-06","last_seen":"2016-07-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001652923","name":"AveXis, Inc.","url":"/issuer/0001652923","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2016-02-19","last_seen":"2016-02-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001130591","name":"XENOPORT INC","url":"/issuer/0001130591","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2016-01-22","last_seen":"2016-01-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001008586","name":"STREAMLINE HEALTH SOLUTIONS INC.","url":"/issuer/0001008586","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2015-12-17","last_seen":"2015-12-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001267602","name":"ALIMERA SCIENCES INC","url":"/issuer/0001267602","role":"Ten percent owner, Other","n_filings":8,"first_seen":"2015-10-09","last_seen":"2015-12-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001501989","name":"CytomX Therapeutics, Inc.","url":"/issuer/0001501989","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2015-10-14","last_seen":"2015-10-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001016169","name":"ANTARES PHARMA, INC.","url":"/issuer/0001016169","role":"Ten percent owner, Other","n_filings":7,"first_seen":"2015-06-15","last_seen":"2015-09-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001467652","name":"Neos Therapeutics, Inc.","url":"/issuer/0001467652","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2015-07-28","last_seen":"2015-07-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001626199","name":"Nivalis Therapeutics, Inc.","url":"/issuer/0001626199","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2015-06-25","last_seen":"2015-06-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001339970","name":"aTYR PHARMA INC","url":"/issuer/0001339970","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2015-05-13","last_seen":"2015-05-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001619087","name":"SteadyMed Ltd.","url":"/issuer/0001619087","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2015-03-25","last_seen":"2015-03-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001501134","name":"Invitae Corp","url":"/issuer/0001501134","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2015-02-19","last_seen":"2015-02-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001454189","name":"Auspex Pharmaceuticals, Inc.","url":"/issuer/0001454189","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2014-02-11","last_seen":"2015-01-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001399529","name":"Dicerna Pharmaceuticals Inc","url":"/issuer/0001399529","role":"Ten percent owner, Other","n_filings":4,"first_seen":"2014-02-04","last_seen":"2014-11-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001359931","name":"PROTEON THERAPEUTICS INC","url":"/issuer/0001359931","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2014-10-27","last_seen":"2014-10-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001581720","name":"Loxo Oncology, Inc.","url":"/issuer/0001581720","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2014-08-06","last_seen":"2014-08-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001501756","name":"Avalanche Biotechnologies, Inc.","url":"/issuer/0001501756","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2014-08-05","last_seen":"2014-08-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001432732","name":"TriVascular Technologies, Inc.","url":"/issuer/0001432732","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2014-04-22","last_seen":"2014-04-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001140028","name":"Talon Therapeutics, Inc.","url":"/issuer/0001140028","role":"Ten percent owner, Other","n_filings":22,"first_seen":"2011-05-19","last_seen":"2013-07-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001034842","name":"RIGEL PHARMACEUTICALS INC","url":"/issuer/0001034842","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2010-11-05","last_seen":"2011-06-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001354395","retrieved_at":"2026-08-26T10:23:59+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}